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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.029Using androgen receptor (AR) knockout mice to determine AR functions in selective prostate cancer
(PCa) cells, we determined that AR might play differential roles in various cell types, either to promote
or suppress PCa development/progression. These observations partially explain the failure of current
androgen deprivation therapy (ADT) to reduce/prevent androgen binding to AR in every cell. Herein, we
identiﬁed the AR degradation enhancer ASC-J9, which selectively degrades AR protein via interruption
of the AR-AR selective coregulator interaction. Such selective interruption could, therefore, suppress
AR-mediated PCa growth in the androgen-sensitive stage before ADT and in the castration-resistant
stage after ADT. Mechanistic dissection suggested that ASC-J9 could activate the proteasome-
dependent pathway to promote AR degradation through the enhanced association of AR-Mdm2
complex. The consequences of ASC-J9-promoted AR degradation included reduced androgen binding to
AR, AR N-C terminal interaction, and AR nuclear translocation. Such inhibitory regulation could then
result in suppression of AR transactivation and AR-mediated cell growth in eight different mouse
models, including intact or castrated nude mice xenografted with androgen-sensitive LNCaP cells
or androgen-insensitive C81 cells and castrated nude mice xenografted with castration-resistant C4-2
and CWR22Rv1 cells, and TRAMP and Ptenþ/ mice. These results demonstrate that ASC-J9 could serve
as an AR degradation enhancer that effectively suppresses PCa development/progression in the
androgen-sensitive and castration-resistant stages. (Am J Pathol 2013, 182: 460e473; http://
dx.doi.org/10.1016/j.ajpath.2012.10.029)Supported by NIH grants (CA127300, CA122840, and CA156700) and
the George Whipple Professorship Endowment.
K.-P.L. and C.-K.H. contributed equally to this work.
Disclosure: ASC-J9 was patented by the University of Rochester, the
University of North Carolina, and AndroScience Corp. and then was
licensed to AndroScience Corp. The University of Rochester and C.C. own
royalties and equity in AndroScience Corp.Androgen/androgen receptor (AR) signaling plays essential
roles in prostate cancer (PCa) progression and results in
castration resistance.1e4 Currently, most, if not all, androgen
deprivation therapy (ADT) targets androgens via surgical
and/or medical castration to reduce/prevent androgen binding
to AR.5 However, few, if any, of these ADTs with various
antiandrogens, including the recently developed enzaluta-
mide,6 have the capacity to eliminate all PCa cells in the later
castration-resistant stage. Therefore, degradation of AR
during/after ADT can be considered to have clinical beneﬁts
for patients with advanced PCa with substantial AR.6 These
conclusions suggest that identifying a novel compound(s)
that could degrade/diminish AR protein in the castration-
resistant stage, unlike currently used antiandrogens, maystigative Pathology.
.yield better therapeutic efﬁcacies to battle PCa in the
castration-resistant stage.
Early studies via isolation of three PCa primary cells
(PCa1, PCa2, and PCa3) from the same patient found that
androgen/AR signaling could function differentially to either
suppress or promote PCa growth.7 Using the cre-loxP
strategy in mice to selectively knockout AR in various PCa
Targeting Prostate Tumor by ASC-J9cells, Niu and colleagues3,4,8 observed that the loss of AR in
cytokeratin 5/cytokeratin 8epositive basal intermediate
epithelial cells led to increased PCa metastasis, yet loss of AR
in cytokeratin 8epositive luminal epithelial cells resulted in
suppressed PCa progression with increased cell apoptosis. In
contrast, loss of AR in stromal ﬁbroblasts and smooth muscle
cells resulted in suppression of prostate/PCa growth.9,10
These results conclude that AR can either promote or
suppress PCa progression in different types of PCa cells.
Because only one AR gene has been identiﬁed,11 we
hypothesized that these differential AR roles in various
PCa cells in the same patient could be due to the existence
of different AR-AR coregulator complexes. This hypoth-
esis led us to screen the AR degradation enhancer
5-hydroxy-1,7-bis(3,4-dimethoxyphenyl)-1,4,6-heptatrien-
3-one (ASC-J9) from natural products and their derivatives
by selectively interrupting the interaction between AR and
selective AR coregulators, such as AReAR-associated
protein (ARA) 70 and AR-ARA55, which are expressed
mainly in luminal epithelial cells and stromal cells, res-
pectively, in which AR may function with positive roles to
either maintain cell survival or promote cell proliferation.
Results from four different human PCa cell lines and eight
different in vivo mouse models concluded that ASC-J9
could function as a promising AR degradation enhancer
to suppress PCa progression before and after castration
resistance with few adverse effects.
Materials and Methods
Mice, Cells, Reagents, and Human Prostate Specimens
The Ptenþ/ mouse (B6/129 background) was originally
obtained from the National Cancer Institute (Bethesda, MD)
and was backcrossed into C57BL/6 background for ﬁve or
six generations. The protocols of Pten genotyping were used
according to the previous report.12 TRAMP mice in FVB or
C57BL/6 background were purchased from The Jackson
Laboratory (Bar Harbor, ME). The tumor chunks from
C57BL/6 TRAMP mice were used for SCID mouse
implantation, and FVB/C57BL/6 TRAMP mice were used
for ASC-J9 injection experiments. Animal study protocols
were approved by the University of Rochester Committee
on Animal Resources, and the mice were kept in a speciﬁc
pathogenefree environment.
PCa cell lines LNCaP, C4-2, C81, CWR22Rv1, and LAPC4
were cultured in RPMI medium supplemented with 10% fetal
bovine serum (FBS), 100 U/mL of penicillin/streptomycin,
and 2mmol/L L-glutamine (Life Technologies, Carlsbad, CA).
Prostate stromal cells WPMY-1 and COS-1 were cultured in
Dulbecco’smodiﬁed Eagle’smedium supplementedwith 10%
FBS, 100 U/mL of penicillin/streptomycin, and 2 mmol/L
L-glutamine (Life Technologies). 5a-Dihydrotestosterone
(DHT; Sigma-Aldrich, St. Louis, MO) was dissolved in 100%
ethanol and was stored at 20C for up to 1 month. Bicalu-
tamide (Casodex) and hydroxyﬂutamide (HF) were purchasedThe American Journal of Pathology - ajp.amjpathol.orgfrom Toronto Research Chemicals (Toronto, Ontario, Canada)
and were dissolved in dimethyl sulfoxide (DMSO). Enzalu-
tamide (formerly known as MDV3100; Selleck Chemicals,
Houston, TX), MG-132 (Sigma-Aldrich), and LY294002
(Calbiochem, Millipore, Billerica, MA) were dissolved in
DMSO. The antibodies for AR (N-20), ARA55, ARA70,
estrogen receptor (ER) a, glucocorticoid receptor (GR),
peroxisome proliferator-activated receptor (PPAR) a, PPARg,
retinoic acid receptora (RARa), murine doubleminute protein
2 (Mdm2), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). The ERb antibody was obtained from
Genoptix (Carlsbad, CA). The antibodies for SRC-1, pAkt at
Ser 473, total Akt, and pMdm2 at S166 were purchased from
Cell SignalingTechnology Inc. (Danvers,MA), andKi-67was
from Novocastra Laboratories Ltd. (Newcastle on Tyne, UK).
The plasmids pDNA3-HA-Ub, dominant-negative Akt (myr-
Akt K179M, T308A, and S473A), and mutant Mdm2 (S166/
186A) were obtained from Addgene (Cambridge, MA).
ASC-J9 was a gift from AndroScience Corp. (San Diego,
CA) and was generated as described previously.13,14 ASC-J9
[dissolved in N,N-dimethylacetamide and diluted with Kol-
liphor EL (formerly known as Cremophor EL; Sigma-
Aldrich) and 0.9% normal saline] was i.p. injected into
mice at a dose of 50, 75, or 100 mg/kg as described until the
end of each study. Control mice received N,N-dimethylace-
tamide, Kolliphor EL, and 0.9% normal saline diluent only.
For the in vitro study, ASC-J9 was dissolved in DMSO at 10
mmol/L and was stored at 20C.
Paired human primary prostate tissues were collected from
the same patients before ADT and after the development of
castration-resistant PCa at Tohoku University Hospital
(Sendai, Japan), Miyagi Cancer Center (Natori, Japan),
and Chang Gung Memorial Hospital (Taipei, Taiwan). The
study was approved by the ethics committees of the three
institutions.
ASC-J9 Characterization
For the study of AR-ARA55 and AR-ARA70 interactions,
WPMY-1 and LNCaP cells were treated with vehicle, bica-
lutamide, or 5 mmol/L ASC-J9 and then were analyzed using
the co-immunoprecipitation (Co-IP) assay. Before drug
treatment, 5 mmol/L MG-132 was added to the culture
medium for 30 minutes to prevent AR protein degradation.15
For the AR-Mdm2 interaction study, we used LNCaP cells
and followed the same protocol as described previously.
For the mammalian two-hybrid assay to determine the AR-
AR coregulator interaction, COS-1 cells were seeded and
transfected with pGal4-RE-Luc reporter plasmid, pCMX-
Gal4-AR-LBD (AR ligand binding domain), pCMX-
VP16-ARA70, or pCMX-VP16-ARA55 plasmids, and we
followed the protocol as described previously.16 The AR
transactivation activity was monitored using ARE4-luciferase
or MMTV-luciferase as previously described.14 For the AR
protein degradation study, LAPC4, LNCaP, C4-2, and461
Lai et alC2R22Rv1 cells were cultured in RPMI medium plus 10%
charcoal-dextranestripped (CDS) FBS for 2 days. The next
day, cells were treated with vehicle or 1 nmol/L DHT and 5,
7.5, or 10 mmol/L ASC-J9 in 10% CDS-FBS RPMI medium.
The treatments with the antiandrogens enzalutamide, bica-
lutamide, and HF were used as controls. After 24 hours of
treatment, the cell lysates were harvested and subjected to AR
and GAPDH Western blot analysis. The stabilities of AR,
GR, ERa, ERb, PPARa, PPARg, and RARa in response to 5
mmol/L ASC-J9 were tested in LNCaP cells (AR and RARa),
PC3 cells (GR, PPARa, and PPARg), and T47D cells (ERa
and ERb) by using Western blot analysis.
Ubiquitination Assay
CWR22Rv1 cells were transiently transfected with
pCDNA3-HA-Ub (Addgene) by Lipofectamine 2000
(Invitrogen, Carlsbad, CA) for 6 to 8 hours. After trans-
fection, the medium was replaced with 10% CDS-FBS
RPMI medium for 24 hours. Then, the cells were treated
with ethanol, 1 nmol/L DHT, or 1 nmol/L DHT/10 mmol/L
ASC-J9 for another 24 hours. The cell extracts were har-
vested and subjected to Co-IP assays. We used HA antibody
(Genoptix) to pull down the ubiquitinated AR and AR
antibody (N-20; Santa Cruz Biotechnology) for the immu-
noblotting assay.
Competitive Binding Studies
Aliquots of the lysates were incubated with 5 nmol/L [3H]
R1881 (90 Ci/mmol) in the absence or presence of unla-
beled corticosteroids (DHT, HF, and ASC-J9, 1  1010 to
1  101 mol/L, in a ﬁnal reaction volume of 100 mL).
Binding of 3H-labeled androgen was measured using the
hydroxyapatite ﬁlter method. The inhibitory concentration
of 50% was determined by measuring the amount of DHT
required to inhibit the binding of 5 nmol/L [3H] R1881 to
AR by 50% and was determined from the competitive
binding curves. The inhibitory concentration of 50% of each
compound was calculated according to the plots of
concentration versus percentage of binding. The experi-
ments were repeated three times to ensure the binding
speciﬁcity. The variations of duplicated assays were within
10% of the average (Supplemental Table S1).
Immunoﬂuorescence Staining
LNCaP cells were cultured in 2-well Chamber slides (Nalge
Nunc International Corp., Rochester, NY) and treated with
vehicle, 1 nmol/L DHT, or 1 nmol/L DHT/5 mmol/L ASC-
J9 in 10% CDS-FBS RPMI medium with the addition of 50
mmol/L cycloheximide (Sigma-Aldrich). Cells were then
ﬁxed and stained with AR antibody, followed by ﬂuores-
cein isothiocyanateeconjugated secondary antibody (Vector
Laboratories, Burlingame, CA). The slides were mounted in
ﬂuorescent mounting medium containing DAPI (Vector462Laboratories). Fluorescent staining was observed using an
Olympus ﬂuorescent microscope (IX71; Olympus America
Inc., Center Valley, PA).Chromatin Immunoprecipitation
C4-2 cells were cultured in 10% CDS-FBS RPMI medium
for 2 days and were treated with vehicle, 1 nmol/L DHT, 5
mmol/L ASC-J9, or 1 nmol/L DHT/5 mmol/L ASC-J9 for 4
hours. The cells were subjected to standard chromatin
immunoprecipitation assay as described previously.13 The
eluted products were detected by using quantitative real-
time PCR, and the AR-binding DNA was pulled down by
using AR antibody (C-19; Santa Cruz Biotechnology). The
input control was used to normalize each treated group, and
IgG control served as negative control.
Cell Growth Assay
C4-2, C81, CWR22Rv1, and LNCaP cells were seeded in
24-well plates at a density of 2000 cells per well in
RPMI medium containing 10% CDS-FBS for 24 hours.
The cells were treated with vehicle, 1 nmol/L/10 nmol/L
DHT, 5 mmol/L HF, 5 mmol/L bicalutamide, or 5 mmol/L
ASC-J9. The medium was replenished every other day, and
cell growth was determined using MTT assay. Serum-free
medium containing MTT (0.5 mg/mL; Sigma-Aldrich)
was added to each well. After 2 hours of incubation at
37C, the medium was removed and DMSO was added
to solubilize the formazan product, and the absorbance
was recorded using an enzyme-linked immunosorbent assay
reader.RNA Extraction, RT-PCR, Quantitative Real-Time PCR,
and Pathway-Focused Superarray Analysis
Total RNAs were prepared from cells using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions.
cDNA synthesis was performed by using RT-PCR with
SuperScript RNase H-Reverse Transcriptase (Invitrogen).
Expression levels of AR-regulated genes were determined
by quantitative real-time PCR using iCycler real-time PCR
ampliﬁer (Bio-Rad Laboratories, Hercules, CA). The rela-
tive copy numbers of GAPDH or b-actin were quantiﬁed
and used for normalization. The DDCT method was used to
calculate relative differential expression between the control
and experimental groups. For the Cancer PathwayFinder
Superarray analysis (PAMM-033; SABioscience, Invi-
trogen), >80 primers corresponding to several category-
related genes (cell cycle control and DNA damage repair,
apoptosis and cell senescence, signal transduction molecules
and transcription factors, adhesion, angiogenesis, and
invasion/metastasis) were precoated on 96-well plates from
SABioscience (Invitrogen). The standard real-time PCR
analysis was used, and the analysis was conducted usingajp.amjpathol.org - The American Journal of Pathology
Targeting Prostate Tumor by ASC-J9website-based software RT2 Proﬁler PCR Array Data
Analysis version 3.5 (Qiagen Inc., Valencia, CA).
Animals Studies
Xenografted Mouse Models
For orthotopic xenografts, C81, C4-2, CWR22Rv1, and
LNCaP cells were harvested, washed with PBS, and resus-
pended in Matrigel (a 1:1 mixture of culture medium and
Matrigel) (BD Biosciences, San Jose, CA). The C81 (2 
106 per site), LNCaP (2  106 per site), C4-2 (5  105 per
site), or CWR22Rv1 (5  105 per site) cells were then
injected orthotopically into two anterior prostate lobes of
nude mice. For the s.c. injection study, LNCaP or C81 cells
(2  106 per site) were injected into two ﬂanks of the 5- to
6-week-old male nude mice.
The effects of ASC-J9 on xenografted tumor growth under
the castration condition. The orthotopic implantation and
surgical castration were performed simultaneously. After 2
to 3 weeks of tumor development, vehicle or 75 mg/kg of
ASC-J9 was given by i.p. injection every other day for 2
weeks (N Z 5 to 6 mice per group).
The effects of ASC-J9 on PCa development/progression
in intact nude mice. For PCa early development, treatment
with ASC-J9 started when LNCaP cells were injected for
xenograft in the ﬂanks. Thirty-six mice were separated into
three groups: vehicle control, 50 mg/kg of ASC-J9, and
implanted HF pellet. Tumor size was monitored twice a week
and was scored as positive (end point) when the size reached
40 mm3. For PCa development/progression, ASC-J9 treatment
was started after the tumor developed (2 to 3 weeks after
xenografts). Mice were randomly separated into three groups
(12mice and 24 tumors per group: vehicle control, 50mg/kg of
ASC-J9, and 100 mg/kg of ASC-J9). The treatment schedule
was twice per week, and the ﬂank tumor size was measured
twice per week using calipers. The following formula was used
to estimate tumor weight: tumor size (mm3) Z tumor length
(mm)  [tumor width (mm)]2 0.5.
TRAMP and Ptenþ/ Mouse Models
For the TRAMP mouse model, C57BL/6/FVB TRAMP
mice were treated with 75 mg/kg of ASC-J9 or vehicle
control through i.p. injections every day at 8 weeks old
(NZ 6 mice per group). Starting at 10 weeks old, the mice
were examined weekly until they were 23 to 24 weeks old.
The mice were euthanized with carbon dioxide, and
necropsy was performed to conﬁrm the presence and origin
of the tumor. For the Ptenþ/ mouse model, 6-month-old
C57BL/6 Ptenþ/ mice were treated with vehicle control or
100 mg/kg of ASC-J9 three times per week for 2 months. At
8 months of age, the prostate tissues were harvested and
subjected to histologic characterization.
TRAMP Mouse Tumor Chunk Implantation
The prostate tumors were harvested from 33- to 34-week-
old C57BL/6 TRAMP mice and cut into 0.2-cm tissueThe American Journal of Pathology - ajp.amjpathol.orgchunks. The tissue chunks were implanted into SCID mice
s.c. or as subrenal capsule implants to examine ASC-J9
therapeutic effects in vivo.
For s.c. implantation, the prostate tumor chunks were s.c.
implanted into SCID mice. After 2 weeks of tumor growth,
vehicle control or 100 mg/kg of ASC-J9 was injected into
SCID mice three times per week. After 4 weeks of treat-
ment, the tumors were harvested and the tumor weights
determined. For subrenal capsule implantation, the prostate
tumor chunks were implanted into SCID mouse subrenal
capsules. After 2 weeks of tumor growth, vehicle control or
100 mg/kg of ASC-J9 was injected into mice three times per
week. After 4 weeks of treatment, the tumors grown under
the subrenal capsule were harvested and the tumor weights
determined.
Histologic Characterization
The xenografted prostate tumor tissues were harvested and
immediately immersed into 10% neutral buffered formalin
for overnight incubation. The tissues were embedded as
parafﬁn blocks and sectioned at 5 mm for H&E staining and
immunohistochemical staining using speciﬁed antibodies.
Tissue slides were prepared, and sodium citrate (pH 6.0)
was applied for antigen retrieval. The 5% bovine serum
albumin and 5% nonfat milk in 0.1% phosphate-buffered
saline/Tween buffer was used for blocking at room
temperature for 1 hour. The primary antibodies against AR
(N-20; Santa Cruz Biotechnology), Ki-67 (Novocastra
Laboratories Ltd.), and SV40-T antigen (Santa Cruz
Biotechnology) were used for hybridization at 4C over-
night, and secondary antibody with conjugated horseradish
peroxidase was applied for staining and substrate develop-
ment. The BrdU staining (Invitrogen) and terminal deoxy-
nucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) assay (Calbiochem) were performed according to
the manufacturer’s instructions.
Statistical Analysis
The experimentswere repeated aminimumof three times, and
the data are presented as mean  SD or mean  SEM.
Statistical signiﬁcance was determined using the t-test (two-
tailed) comparison between two groups of data sets. One-way
analysis of variance was used to compare more than two
groups. P < 0.05, P < 0.01, and P < 0.001 were considered
statistically signiﬁcant depending on the experiment.
Results
ASC-J9 Interrupts the Interaction between AR and AR
Coregulators ARA55 and ARA70 in Prostate Stromal
WPMY-1 and Luminal Epithelial LNCaP Cells
To selectively target AR in PCa stromal and/or luminal epith-
elial cells in PCa progression, we started with a comprehensive463
Lai et altissue survey to examine the expressions of previously identi-
ﬁed AR coregulators17 and, consistent with previous reports,
identiﬁed ARA55 and ARA70 expression, mainly in stromal
and luminal epithelial cells, respectively.16,18 We then scr-
eened natural products and their derivatives to determine which
ones could interrupt the interaction between AR-ARA55 in
prostate stromal WPMY-1 cells and/or AR-ARA70 in luminal
epithelial LNCaP cells. We found that ASC-J9, but not the
currently used antiandrogens, such as bicalutamide, could
promote the dissociation of AR-ARA55 complex in WPMY-1
cells by using the Co-IP assay and the mammalian two-hybrid
assay (Figure 1A). A similar observation was seen in AR-
ARA70 complex in LNCaP cells with ASC-J9 treatment
(Figure 1B).
Such interrupted association of AR-ARA55 in WPMY-1
cells and of AR-ARA70 in LNCaP cells resulted in
suppression of stromal ARetargeted gene keratinocyteFigure 1 ASC-J9 selectively promotes AR degradation via interrupting the inter
between AR and ARA55 in WPMY-1 cells. Top and middle panels: Co-IP assay of t
The 5 mmol/L proteasome inhibitor MG-132 was added for 30 minutes before addin
protein degradation. The quantitation data of Co-IP are presented as fold increase
loading controls show similar amounts. Bottom panel: The mammalian two-hybr
interaction between AR and ARA55. B: ASC-J9, 5 mmol/L, dissociated the binding o
complex in LNCaP cells, with or without ASC-J9 treatment, and determined by im
quantitation of Co-IP results are presented as fold increase compared with the V
interaction between AR-ARA70 by mammalian two-hybrid assay. C: The reduction o
and PSA levels in LNCaP cells (bottom panel) after 5-mmol/L ASC-J9 treatments.
WPMY-1 (top panel) and LNCaP cells (bottom panel) after DHT stimulation. EeG: A
after HF, bicalutamide, or 17b-estradiol (E2) treatment using MMTV-Luc reporte
(ARA70N), and mutant AR (T877A AR) are shown. Error bars Z mean  SD. RLA
464growth factor and epithelial ARetargeted gene prostate
speciﬁc antigen (PSA) expression (Figure 1C). We found
that ASC-J9 had less effect in interrupting the interaction
between AR and AR coregulator SRC-1 in LNCaP cells
(Supplemental Figure S1), suggesting that ASC-J9 could
differentially interrupt the interactions between AR and
selective AR coregulators.
Together, the results from Figure 1, AeC, demonstrate that
interruption of the AR-ARA55 interaction in WPMY-1
stromal cells and the AR-ARA70 interaction in LNCaP
luminal epithelial cells suppressedAR transcriptional activity,
which was further conﬁrmed using the (ARE)4-luciferase
assay (Figure 1D).We found that ASC-J9 could also suppress
HF-, bicalutamide-, and 17b-estradioleinduced AR trans-
activation in the presence of ARA70, which might contribute
to the androgen-independent AR-mediated PCa progression
in the castration-resistant stage (Figure 1, EeG).19action between AR and AR coregulators. A: ASC-J9 disrupted the interaction
he AR-ARA55 complex in WPMY-1 cells examined by immunoblotting assay.
g the vehicle (Veh), 5 mmol/L bicalutamide, or 5 mmol/L ASC-J9 to prevent
compared with the Veh group by densitometric analysis of bands. The input
id assay was used to demonstrate that 5 mmol/L ASC-J9 can suppress the
f AR and ARA70 in LNCaP cells. Top and middle panels: Co-IP of AR-ARA70
munoblotting assay. MG-132 at 5 mmol/L was added before treatment. The
eh group. Bottom panel: ASC-J9 also showed the inhibitory effects on the
f keratinocyte growth factor (KGF) mRNA levels in WPMY-1 cells (top panel)
D: ASC-J9, 5 mmol/L, treatment reduced (ARE)4-luciferase (Luc) activity in
SC-J9 suppressed ARA70-mediated AR transcriptional activity in COS-1 cells
r assay. ARA70 full-length (ARA70F), ARA70 N-terminal amino acid 1-401
, relative luciferase activity.
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The initial goal was to identify a novel anti-AR com-
pound(s) via screening natural products and their derivatives
that could interrupt the interactions between AR and its
selective AR coregulators in prostate stromal and luminal
epithelial cells. Dissociation of the AR-coregulator complex
could then result in the suppression of AR transcriptional
activity. We found that AR, after being dissociated from
selective coregulators, such as ARA55 or ARA70, became
more susceptible to be degraded. Results from Western blot
analysis showed that AR proteins in LAPC4 (wild-type AR)
and LNCaP (mutant T877A AR) cells were substantially
reduced after the addition of ASC-J9 in a dose-dependent
manner (Figure 2A). These results were unequivocally
observed in other castration-resistant PCa cell lines (C4-2
and CWR22Rv1) (Figure 2B). ASC-J9, but not the currently
used or newly developed antiandrogens (bicalutamide, HF,
or enzalutamide) (see Supplemental Figure S2 for each
compound’s structure), could promote the degradation of
full-length AR in the LAPC4, LNCaP, C4-2, and
CWR22Rv1 cells as well as the splice variant AR3 in the
CWR22Rv1 cells (Figure 2, A and B, and Supplemental
Figure S3).
The enhanced AR ubiquitination after ASC-J9 treatment
seems to be one of the key mechanisms to promote ARThe American Journal of Pathology - ajp.amjpathol.orgprotein degradation (Supplemental Figure S4). In contrast,
AR mRNA did not show marked changes after ASC-J9
treatment in the CWR22Rv1,20 LNCaP, and C4-2 cells
(K.-P.L., unpublished data). We also assayed the ASC-J9
degradation efﬁciency on other nuclear receptors in
various cells, including LNCaP, PC-3, and T47D cells,
because some endogenous nuclear receptors are expressed
only in certain types of cells. We found that ASC-J9 had
a better degradation capacity on AR (LNCaP) than on
other nuclear receptors, such as GR (PC-3), PPAR-a (PC-
3), PPAR-g (PC-3), RARa (LNCaP), ERa (T47D), and
ERb (T47D) (Figure 2C). As different cells have differ-
ential expression of nuclear receptors with their various
associated coregulators under various concentrations of
their agonists/antagonists, we might expect to see the
variant degradation capacity of individual nuclear recep-
tors with ASC-J9 treatment. A comprehensive in vivo
toxicity study in the future may provide a better answer
whether ASC-J9 may have any severe adverse effects due
to targeting other proteins, including various nuclear
receptors.
To dissect the molecular mechanisms by which ASC-J9
degrades AR, we tested whether ASC-J9 could inﬂuence
protease degradation pathways by examining AR-Mdm2
complex formation. We found that ASC-J9 could increase
the interaction of AR-Mdm2 complex in LNCaP cellsFigure 2 ASC-J9 enhances AR protein degrada-
tion through the proteasome-dependent pathway. A:
ASC-J9, but not enzalutamide, bicalutamide, or HF,
could enhance the degradation of AR proteins in
LAPC4 cells and LNCaP cells using Western blot
analysis. B: ASC-J9 degraded AR protein in
castration-resistant C4-2 cells and CWR22Rv1 cells.
The full blots of the enzalutamide-treated group are
provided in Supplemental Figure S3. C: ASC-J9 had
a higher degradation capacity on AR protein
compared with effects on GR, ERa, ERb, PPARa,
PPARg, and RARa Western blot analysis. The protein
amounts of AR, GR, ERa, ERb, PPARa, PPARg, and
RARa in response to 5mmol/L ASC-J9was determined
in LNCaP cells (AR and RARa), PC3 cells (GR, PPARa,
and PPARg), and T47D breast cancer cells (ERa and
ERb). The GAPDH loading control is shown for the
LNCaP cells, and GAPDH amounts in the vehicle-
treated or ASC-J9etreated group were also similar
in PC-3 and T47D cells (data not shown). D: The
interaction between AR and Mdm2 was increased in
MG-132 pre-treated LNCaP cells, after 5-mmol/L
ASC-J9 treatments using Co-IP followed by immu-
noblotting assay. The quantitation data of Co-IP are
presented as fold increase compared with the vehicle
(Veh) group. E: The AR protein degradation mediated
by 5 mmol/L ASC-J9 in LNCaP cells was partially
reversed by treating with 5 mmol/L LY294002 (LY) 30
minutes before ASC-J9 treatment. Western blot
analysis was used to characterize AR, pAkt (S473),
total Akt, and GAPDH protein amounts. EtOH,
ethanol.
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Lai et al(Figure 2D) and the phosphorylationsofAkt andMdm2,which
are the key molecules involved in the proteasome-dependent
pathways in C4-2 and CWR22Rv1 cells (Supplemental
Figure S5). Supportively, co-treatment of ASC-J9 with the
inhibitor of the PI3K/Akt (LY294002) could partially reverse
AR degradation (Figure 2E). These results were further
conﬁrmed by reintroducing dominant-negative Akt (dAkt,
K179M, S473A, T308A) and/or mutant Mdm2 (S166/186A)
into the CWR22Rv1 cells to partially reverse ASC-J9e
mediated AR degradation (Supplemental Figure S6), sug-
gesting that ASC-J9 might promote AR degradation via the
proteasome degradation pathway.21
Collectively, we conclude that ASC-J9 can enhance the
association of AR-Mdm2, and, therefore, AR becomes more
susceptible to be degraded by proteasomes (after dissocia-
tion of selective ARA interactions).Figure 3 ASC-J9 abolishes androgen/AR signal pathways. A: ASC-J9 interrupted
the dual luciferase systems. B: ASC-J9 blocked AR nuclear translocation stimulated b
AR localization. Green indicates AR protein and blue labels DAPI nuclear staining. C:
regions in C4-2 cells using chromatin immunoprecipitation assay. The quantitative
TMPRSS2 promoter regions. D: ASC-J9 displayed better suppressive effects on AR-targ
The gene expression levels were determined using quantitative PCR analysis and n
466ASC-J9 Suppresses AR Transcriptional Activity through
Protein Degradation
The consequences of such dissociation between AR and its
selective AR coregulators via ASC-J9 might also lead to the
decreased binding of androgens to AR. For relative ligand
binding assays, aliquots of LNCaP cell lysates with
synthetic androgene[3H] R1881 were incubated with
increasing concentrations of unlabeled DHT, HF, and ASC-
J9, and results showed that ASC-J9 was able to interfere
with the androgen binding (Supplemental Table S1).
ASC-J9 also disrupted the AR amino- and carboxyl-
terminal (N-C) interaction that is important in mediating AR
transactivation.22 As shown in Figure 3A, DHT could
promote AR N-C interaction, and the addition of ASC-J9
was able to block the AR N-C interaction.the AR N-C terminal interaction using the mammalian two-hybrid assay and
y DHT in LNCaP cells. Immunoﬂuorescent staining was performed to determine
ASC-J9 suppressed DHT-induced AR recruitment to PSA and TMPRSS2 promoter
PCR results are shown from the ampliﬁcation of immunoprecipitated PSA and
eted genes FKBP5, PSA, and TMPRSS2 than bicalutamide and HF in C4-2 cells.
ormalized with GAPDH. Error bars Z mean  SD.
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was blocked by co-treatment with ASC-J9 (Figure 3B).
Chromatin immunoprecipitation binding assays demon-
strated that ASC-J9 inhibited the recruitment of AR protein
to its targeted genes (PSA and TMPRSS2) promoter regions
(Figure 3C).
The consequences of the interrupted intracellular AR
signals/shuttle by ASC-J9might then result in better inhibition
ofAR-targeted gene expression (FKBP5,PSA, andTMPRSS2)
than the currently used antiandrogens (bicalutamide and HF)
in C4-2 cells (Figure 3D) and C81 (Supplemental Figure S7).
In contrast, HF is a strong agonist for mutant AR in LNCaP,
C4-2, and C81 cells.
Together, results from Figure 3 demonstrate that AR
could be more easily degraded by ASC-J9 through disso-
ciation of AR and selective AR coregulators. The AR
degradation by ASC-J9, therefore, interfered with androgen/
AR binding, AR N-C interaction, AR nuclear translocation,
and AR recruitment to the targeted gene promoter region,
which might then suppress AR transactivation and its tar-
geted gene expressions.
ASC-J9 Inhibits PCa Cell Growth in C4-2, C81,
CWR22Rv1, and LNCaP Cells
To determine the consequences of AR degradation mediated
by ASC-J9, we tested the growth of AR-positive PCa cells.
We ﬁrst examined castration-resistant C4-2, C81, and
CWR22Rv1 cells23e25 and found that ASC-J9 signiﬁcantly)
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Figure 4 ASC-J9 inhibits cell growth in androgen-sensitive and castration-resist
in castration-resistant C4-2, C81, and CWR22Rv1 cells and androgen-sensitive LNCaP
10 nmol/L DHT condition (B). All cell growth studies were monitored using the MT
The American Journal of Pathology - ajp.amjpathol.orginhibited cell growth in these three types of cells in the pres-
ence of 1 nmol/L DHT (human prostate DHT concentration
after ADT) (Figure 4A)26,27 or 10 nmol/L DHT (human
prostate DHT concentration before ADT) (Figure 4B) with
better efﬁcacy than the currently used antiandrogens, such as
bicalutamide and HF (Figure 4).28e30
We also examined ASC-J9 effects on LNCaP cells that
represent androgen-sensitive PCa before ADT.25,31,32 We
conﬁrmed that ASC-J9 signiﬁcantly inhibited cell growth of
LNCaP cells in the presence of 1 or 10 nmol/L DHT (Figure 4,
A and B). Collectively, the results from Figure 4 demonstrate
that ASC-J9 could effectively suppress cell growth of the
androgen-sensitive and castration-resistant PCa cells.
ASC-J9 Suppresses Tumor Growth of C81, C4-2, and
CWR22Rv1 Cells Xenografted into Castrated Nude Mice
To demonstrate ASC-J9 in vivo effects, we then applied
in vivo xenografts in castrated mouse models, which were
recently used to characterize the therapeutic effects of the
newly developed antiandrogens (RD162 and enzaluta-
mide).6 We orthotopically injected the castration-resistant
PCa cells (C81, C4-2, and CWR22Rv1) into the cas-
trated nude mice that have nearly undetectable serum
testosterone33 and observed that the xenografted C81, C4-
2, and CWR22Rv1 cells were able to grow, indicating that
the castration-resistant PCa could not be eliminated even
after removal of almost all endogenous androgens. In
contrast, i.p. injection of ASC-J9 (75 mg/kg of body2Rv1 LNCaP
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ant PCa cells. ASC-J9, 5 mmol/L, treatment substantially inhibited cell growth
cells in the presence of 1 nmol/L DHT using the MTT assay (A) and under the
T assay and conﬁrmed by the cell counting method. EtOH, ethanol.
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Lai et alweight every other day) could signiﬁcantly suppress the
C81 xenografted tumor growth compared with the vehicle
controletreated group (Figure 5A). Similar results were
obtained when we replaced C81 cells with C4-2 cells
(Figure 5B) or CWR22Rv1 cells (Figure 5C). The histo-
logic results of H&E, AR, Ki-67, and TUNEL staining inFigure 5 The in vivo antitumor and chemopreventive effects of ASC-J9 in the xen
in castrated nude mice. C81 cells were orthotopically implanted into anterior prostat
with vehicle or 75 mg/kg of ASC-J9 every other day. The tumors were harvested afte
fromﬁve to sixmice per group (left panel) and the quantitation data of tumorweight
in castrated nude mice. C: ASC-J9 inhibited CWR22Rv1 xenografted tumor growth i
panel) and androgen-insensitive C81 (right panel) xenografted tumor growth in inta
starting2 to 3weeks after s.c. implantation. Thegross appearance of LNCaP andC81x
panels) are shown. Scale bars: 200 mm (original magniﬁcation,100) and 50 mm (o
xenografted tumor growth in vivo. LNCaP cells were orthotopically implanted into ant
then castrated, and ASC-J9 treatment was started 5 days after castration. The tumor
treatment shows signiﬁcant delayed tumor incidence compared with the vehicle- an
implanted into 4-week-old nude mice when LNCaP cells were s.c. injected into the ﬂ
468C81, C4-2, and CWR22Rv1 xenografted tumors were also
examined to show ASC-J9 effects (Supplemental Figures
S8 and S9). Together, these results showed that ASC-J9
could effectively degrade AR in vivo, resulting in sup-
pressed cell proliferation and enhanced apoptosis in xen-
ografted tumors.ograft mouse PCamodel. A: ASC-J9 suppressed C81 xenografted tumor growth
es of castrated nude mice and grown for 3 to 4 weeks. Mice were then treated
r 3 weeks of treatment. The representative gross appearances of eight tumors
s (right panel) are shown.B: ASC-J9 inhibited tumor growth of C4-2 xenograft
n castrated nude mice. D: ASC-J9 suppressed androgen-sensitive LNCaP (left
ct nudemice. The 50 or 100mg/kg of ASC-J9 was administered twice per week
enografted nudemice (toppanels) and thedissectedprostate tumors (bottom
riginal magniﬁcation,400) E: ASC-J9 suppressed castration-resistant LNCaP
erior prostates of intact nudemice andwere grown for 25 to 28 days. Micewere
s were harvested after 2 weeks of treatment. NZ 4 mice per group. F: ASC-J9
d ﬂutamide-treated groups. The ASC-J9 was injected or a ﬂutamide pellet was
anks. The palpable tumor formation was checked weekly.
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in Intact Nude Mice
We further conﬁrmed ASC-J9 therapeutic effects in a second
mouse model using LNCaP and C81 cells xenografted into
nude mice without castration (to mimic human PCa devel-
opment before ADT), and the results consistently showed that
the i.p. injection of low-dose (50 mg/kg) or high-dose (100
mg/kg) ASC-J9 in mice showed signiﬁcant inhibition of
tumor growth compared with vehicle control mice (Figure 5D
and Supplemental Figure S10), with little inﬂuence on their
body weights (Supplemental Figure S10B).
We subsequently applied a third in vivomouse model with
xenografted LNCaP cells in intact mice and then castrated
these nude mice after 1 month of tumor growth to examine
PCa progression before and after castration. We found that
the castration-resistant LNCaP xenografted tumors remained
sizeable after castration treatment (Figure 5E). In contrast,
ASC-J9 could further inhibit xenografted tumor growth after
castration compared with the mice receiving castration only
(Figure 5E). The histologic characterizations were shown
and demonstrated that ASC-J9 inhibited cell proliferation
and increased apoptosis through AR degradation in vivo
(Supplemental Figure S9, B and D).
If we injected ASC-J9 at the time point when we started
to xenograft LNCaP cells, we found that ASC-J9, but not
HF ﬂutamide, could also delay the xenografted tumor
development (Figure 5F).
Taken together, the evidence from three different mouse
models suggest that ASC-J9 could suppress the growth of
prostate tumors with treatment starting at i) the castration-
resistant stage after ADT (Figure 5, AeC), ii) the stage
being transitioned from before to after ADT (Figure 5, D
and E), and iii) initial PCa growth stage (Figure 5F).
Therapeutic and Chemopreventive Effects of ASC-J9 in
Spontaneous PCa Development TRAMP Mouse Models
There are few perfect PCa mouse models that can mimic
human PCa development/progression. Therefore, we
decided to use the two currently available spontaneous PCa
development mouse models (transgenic adenocarcinoma of
the mouse prostate, TRAMP, and phosphatase and tensin
homolog, Ptenþ/) to further conﬁrm the ASC-J9 in vivo
effect, as we believe that the xenografted mouse models
might have limitations when attempting to mimic the
physiologic condition of the prostate microenvironment.
We performed i.p. injection of 75 mg/kg of ASC-J9 daily
into 8-week-old C57BL/6/FVB TRAMP mice34 (that have
already developed precancerous lesions) for 4 months, and
results showed that ASC-J9 could suppress tumor develop-
ment (Figure 6A). The body weights of the ASC-J9einjected
mice were comparable with the vehicle-treated mice
(Supplemental Figure S11A). Moreover, H&E staining and
SV40-Tag immunohistochemical staining were concurrently
examined (Supplemental Figure S11B) to demonstrate thatThe American Journal of Pathology - ajp.amjpathol.orgASC-J9 could effectively suppress PCa progression. In
addition, we also performed AR immunohistochemical
staining, BrdU staining for proliferation assay, and the
TUNEL apoptosis assay to characterize PCa tumor growth
between the vehicle- and ASC-J9etreated groups. The results
indicate that ASC-J9 was able to decrease AR protein levels,
reduce proliferation, and increase apoptosis (Supplemental
Figure S11, C and D).
We then applied another approach using 33- to 34-week-old
TRAMP mouse prostate tumor chunks (cut into 0.2-cm tissue
chunks), s.c. implanted into SCIDmice to conﬁrm theASC-J9
in vivo effect. After 2 weeks of implantation, vehicle or ASC-
J9was injected every other day for 4weeks before harvest. The
results consistently showed that subcutaneous tumor size/
weight was signiﬁcantly reduced in the ASC-J9etreated mice
(Figure 6B). H&E staining of the subcutaneous TRAMP
tumors and assays of AR protein, BrdU, and TUNEL were
examined (Supplemental Figure S12, A-C). The results
demonstrate that ASC-J9 could effectively degrade AR
in vivo, leading to the inhibition of TRAMP tumor growth.
We further conﬁrmed this ﬁnding by implanting TRAMP
mouse prostate tumor chunks into the renal capsule of SCID
mice to validate the ASC-J9 effects, and we obtained results
similar to those for the s.c. implanted tumors (Figure 6C).
It has been known that the expression of SV40-Tag in
TRAMP mice is driven by the probasin promoter, in which
androgen/AR plays a crucial regulatory role. The previous
report has documented that castration in TRAMP mice could
cause some tumor regression; however, some of the tumors
still continue to grow, indicating the heterogeneity of the
primary tumor, and the overall progression to poorly diff-
erentiated and metastatic tumor was not ultimately delayed
after castration.35 Further analysis of AR and SV40-Tag
after castration found that the AR level was signiﬁcantly
elevated, but SV40-Tag expression almost disappeared 10
weeks after castration.35 Critically, 20 weeks after castration,
the expression level of SV40-Tag was comparable with that
of intact mice, suggesting that probasin promoter still could
function normally 20 weeks after castration; therefore, other
transcriptional machinery might be able to account for the
promoter activation under castration.35 Overall, castration
could initially inhibit SV40-Tag expression through the
suppression of androgen/AR signals; however, 20 weeks
after castration, the SV40-Tag level was relatively compa-
rable.36 In this regard, we observed that ASC-J9 suppressed
TRAMP mouse tumor progression was not due to early
inhibition of SV40-Tag transgene expression alone. More
importantly, the suppression of AR-mediated tumor growth
might be one of the reasons that ASC-J9 could suppress PCa
development in TRAMP mice.
Chemopreventive Effects of ASC-J9 in Ptenþ/ Mouse
Models
Next, we applied the second mouse model (Ptenþ/ mouse)
that could spontaneously develop precancerous lesions to469
Figure 6 In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed
tumor initiation/progression in the TRAMP mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with
continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the
prostate mass weights were calculated (right panel). NZ 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks s.c. implanted
into SCIDmice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated
(bottompanel). NZ 6 for each group. C: TRAMP prostate tumor growthwas inhibited by ASC-J9 after subrenal capsule implantation in SCIDmice. After 4 weeks of
vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). NZ 3 for each group.
D: ASC-J9 displayed chemopreventive effects in the Ptenþ/mousemodel. ASC-J9 was administrated to 6-month-old Ptenþ/mice, and the dorsolateral prostates
were harvested 2 months after injection. Histologic examination of 8-month-old Ptenþ/þ DMSO, Ptenþ/ DMSO, and Ptenþ/ ASC-J9etreated prostates were
subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel.
NZ 5 to 6 mice per group. Error barsZ mean  SEM. Scale bars: 200 mm (original magniﬁcation, 100) and 50mm (original magnifcation, 400).
Lai et alconﬁrm the ASC-J9 effect. Unlike TRAMP mice, Ptenþ/
mice developed only low-/high-grade prostatic intra-
epithelial neoplasia (PIN) lesions.12 Early reports (in
humans) indicated that approximately 5% to 10% of high-
grade PIN could be detected via the needle prostate
biopsy,37 and it is considered as an early stage of PCa,38470with a 50% to 75% high risk of subsequent PCa develop-
ment.39 To prove the ASC-J9 effects, we started injection of
either vehicle or ASC-J9 into 6-month-old Ptenþ/ mice
every other day for 2 months and harvested the prostate
tissues for histologic characterization. We observed that the
dorsolateral prostates from ASC-J9-injected Ptenþ/ miceajp.amjpathol.org - The American Journal of Pathology
Targeting Prostate Tumor by ASC-J9showed diminished high-grade PIN formation, and the
quantitation data are provided (Figure 6D).
Together, results from the previously mentioned two
mouse models (TRAMP and Ptenþ/) conﬁrm the previous
xenografted tumor results (Figure 5) and demonstrate that
ASC-J9 treatment represents a more effective antitumor
therapy compared with the currently used surgical or
medical castration. More important, ASC-J9 might represent
the ﬁrst anti-AR compound that could further suppress
tumor growth after ADT in the castration-resistant stage.
Few Adverse Effects and Little Toxicity in Mice Treated
with ASC-J9
During the in vivo mouse studies, as described in Figures 5
and 6, we observed that the mice receiving ASC-J9 (50 to
100 mg/kg of body weight) showed few adverse effects.
Their body weights were similar to those of the control mice
(Supplemental Figures S10B and S11A). More importantly,
we observed that the ASC-J9etreated mice had normal
serum testosterone levels with normal sexual activity
(judged by vaginal plug numbers in female mice caged with
the treated males14), suggesting that there was little adverse
inﬂuence on serum testosterone in the sexual functions in
the ASC-J9etreated mice. This is important for improve-
ment of the quality of life for patients with PCa receiving
the current ADT with adverse effects of low serum testos-
terone concentrations and decreased libido.40
Moreover, using ASC-J9 as an AR degradation enhancer
to treat acne vulgaris, AndroScience Corp. has completed
phase 1 studies (in healthy individuals and patients with
acne, separately) and phase 2 trial (in patients with acne),
and results showed few adverse effects in these trials.Discussion
The initial screening strategy to identify ASC-J9 was based
on interruption of the AR-ARA55 and/or AR-ARA70
complex that exists mainly in either prostate stromal or
luminal epithelial cells, in which AR functions as positive
roles to promote PCa progression. We found that the mice
receiving ASC-J9 had normal body weight with normal
serum testosterone levels and sexual activity with few
adverse effects, suggesting that ASC-J9 could be different
from the current antiandrogens, such as HF, bicalutamide,
and enzalutamide, which reduce/prevent androgens from
binding to the AR in the whole body and cause adverse
effects, including decreased libido. Because stromal cells
and luminal epithelial cells exist in most stages of PCa,
including before and after ADT (Supplemental Figure S13),
and continue to promote PCa progression,3,4,41 we believe
that targeting AR in selective cells via ASC-J9 might
represent a better strategy for battling PCa.
More importantly, this strategy could be applicable to
inhibiting tumor growth in the castration-resistant stage (seeThe American Journal of Pathology - ajp.amjpathol.orgresults in mice under castration conditions that have nearly
undetectable serum androgen levels in Figure 5, AeC and E,
and human PCa cells at the ADT condition of 1 nmol/L DHT
in Figure 4A), showing that ASC-J9, but not the surgical or
chemical castration, could further suppress PCa growth,
suggesting that targeting AR protein degradation instead of
targeting androgens may represent a new and better strategy
for battling PCa in the castration-resistant stage.
Molecular mechanism dissection suggested the following
conclusions. First, ASC-J9 might interrupt the interaction
betweenARand selective coregulators that leads to promotion
of AR degradation via the proteasome degradation pathway.
The activation of Akt and Mdm2 by ASC-J9 treatment could
subsequently trigger AR ubiquitination, resulting in AR
degradation. Second, ASC-J9emediated AR degradation
might consequently abolish androgen-AR binding, AR N-C
interaction, AR nuclear translocation, and AR recruitment to
targeted gene promoter regions, leading to the inhibition of
AR transcriptional activity. Third, ASC-J9emediated AR
degradation might thereby suppress PCa progression through
the alteration of multiple signal pathways. Using gene array
and subsequent real-time-PCR analyses to examine genes
related to PCa progression,42,43 we found that ASC-
J9etreated LNCaP/C81 xenografted tumors had reduced
expression of angiogenesis and metastasis-related genes, such
as bFGF, VEGF, and MMP9 (Supplemental Figure S14A).
Moreover, ASC-J9 also modulated the toll-like receptor 3
pathway and its downstream caspase gene expressions
(Caspase 3, 8, 9), as well as the proapoptotic protein (BAX),
and apoptosis-inducing factor in LNCaP cells (Supplemental
Figure S14B). This was further conﬁrmed in the ASC-
J9etreated TRAMPmouse tumors by showing elevated levels
of several apoptosis-related genes, such as tumor necrosis
factor (TNF ), caspase-8 (Casp8), CASP8 and FADD-like
apoptosis regulator (Cﬂar), and telomerase reverse transcrip-
tase (Tert) (Supplemental Figure S14C and Supplemental
Table S2). The gene array data from multiple ASC-
J9etreated tumors led us to conclude that interference of
androgen/AR signals by ASC-J9 might, therefore, modulate
multiple signal pathways to suppress PCa growth/progression.
Removal of androgen by ADT causes PCa cell
apoptosis,44 yet tumors may still develop castration resis-
tance even at 1 to 3 nmol/L minimal castrated level of
androgens.45 Indeed, more evidence indicates that castration-
resistant prostate tumors still maintain relatively higher AR
amounts via either AR gene ampliﬁcation or other mecha-
nisms.46 The current ADTwith available antiandrogens, such
as bicalutamide, HF, and enzalutamide (that showed better
efﬁcacy to inhibit androgen binding to AR), all failed to
target and degrade the remaining AR in prostate tumors at the
castration-resistant stage.6 Similarly, the azole antifungal
agent ketoconazole47 or abiraterone acetate,48 which could
suppress the biosynthesis of adrenal androgens, also failed to
ablate the remaining AR; although clinical trials had shown
that these compounds could increase median survival with
decreased PSA levels in patients.49471
Lai et alEarly studies suggested that the AR splice variants might
contribute to the progression of PCa into castration resis-
tance, especially the most dominant variant AR-V7/AR3,
which lacks the portion of the androgen-binding domain;
whereas, the current antiandrogens failed to suppress AR3-
mediated transcriptional activity.50 It has been suggested
that the constitutively active AR3 relies on full-length AR to
exert the AR transcriptional activity and cell growth in
LNCaP-AR cells.51 However, another study also demon-
strated that AR3 itself might contribute to promoting cell
growth.50 Therefore, it would be better to target full-length
AR and AR3 to achieve superior therapeutic efﬁcacy in
castration-resistant PCa. In a previous report20 and the
present study (Figure 2B), we showed that ASC-J9 could
degrade full-length AR and AR3 in CWR22Rv1 cells.
In summary, this study characterizes the ﬁrst AR degra-
dation enhancer, ASC-J9, which is different from the
currently used antiandrogens that could selectively degrade
AR protein to suppress AR signaling and tumor growth
in vitro and in vivo. The success of tumor regression with
ASC-J9 in androgen-dependent and castration-resistant PCa
may provide a new and more effective therapeutic approach
for battling PCa in future.
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